The EU butts heads with Big Pharma to make medicines cheaper

By Staff Writer

February 2, 2023

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity

By João L. Carapinha

The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Urgent Call to Action for EU Clinical Trials Strategy

By Staff Writer

July 28, 2025

The European Federation of Pharmaceutical Industries Associations (EFPIA) warns of Europe’s declining clinical trial opportunities. It stresses the need for the EU clinical trials strategy to tackle these issues. Since 2013, Europe has lost 60,000 trial spots, with trials shifting to the U.S. and...